SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1
Document Type: S-1
Date Filed: 2026-02-12
Accession Number: 0001493152-26-006407
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226006407/forms-1.htm

Chunk 50 of 83
Word Count: 1500
Character Count: 9847

Document Content:

In addition to his role at BioVentrix, Dr. Ben-Yehuda is a Professor of Medicine at the University of California, San Diego (UCSD), where he leads the Cardiovascular Outcomes Group at the Sulpizio Cardiovascular Institute. Dr. Ben-Yehuda also holds editorial positions as Editor-in-Chief of Coronary Artery Disease and Deputy Editor of Structural Heart: The Journal of the Heart Team. Dr. Ben-Yehuda’s previous roles include Executive Director of the Clinical Trials Center at the Cardiovascular Research Foundation and Vice President of Cardiovascular Clinical Trials at Gilead Sciences. Dr. Ben-Yehuda has authored and co-authored over 200 peer-reviewed publications and has been recognized with multiple awards, including Top Abstract at the TCT Conference in 2017 and the Sackler Faculty Prize for Excellence for his MD thesis. Dr. Ben-Yehuda earned his medical degree from the Sackler School of Medicine at Tel Aviv University in Israel and completed a cardiovascular medicine fellowship at UCSD. Independent Directors

Mark
H. Ravich has served as a director since July 2025. Since June 2017, Mr. Ravich has been a director of Rockwell
Medical (Nasdaq: RMTI), a pharmaceutical company, and is currently a member of its audit committee. Mr. Ravich also currently serves
as president of Tri-Star Management, Inc., a commercial real estate management and syndication company that he co-founded in 1998. From
October 2010 through December 2022, Mr. Ravich served as a director of Dilon Technologies, Inc., a designer and manufacturer of medical
imaging solutions. In addition, from February 2019 to March 2023, Mr. Ravich previously served as a director of BioVentrix. Previously,
from February 2013 to 2018, Mr. Ravich served as a director of Orchids Paper Products Company, a national supplier of high-quality consumer
tissue products, as well as chairman of its governance committee and as a member of its audit committee. Orchids Paper Products Company
filed for Chapter 11 bankruptcy on April 1, 2019, in the U.S. Bankruptcy Court for the District of Delaware. From June 2004 to 2018,
Mr. Ravich served as a director of MR Instruments, Inc., an independent designer and manufacturer of advanced MRI Radiofrequency coils.
From 1990 until its sale in 1998, Mr. Ravich served as the chief executive officer and a director of Universal International, Inc., a
wholesale retail company, where he also led its initial public offering. From 1978 to 1990, Mr. Ravich was a developer of commercial
real estate where he was involved with all aspects of development, finance, construction, marketing, leasing and management of various
commercial, industrial, office and multi-family real estate projects. Mr. Ravich began his career in 1975 as an account officer at Citibank
N.A., where he made real estate construction loans to national real estate developers. Mr. Ravich also is the chief manager of various
real estate entities. Mr. Ravich graduated Magna Cum Laude from the Wharton School of the University of Pennsylvania with a B.S. and
an M.B.A. degree with a major in finance. We believe that Mr. Ravich’s extensive board experience across the pharmaceutical, medical
device, and real estate sectors, combined with his financial expertise and leadership in both public and private companies qualifies
him to be a member of our board of directors.

Rishi
Puri, M.D., Ph.D., FRACP, FACC has served as a director since July 2025.

Dr. Puri has been
a coronary and structural interventional cardiologist at the Cleveland Clinic since 2018. With his appointment he was also named
an Associate Professor of Medicine and Medical Director of the Angiography & IVUS Core Laboratory and has also served in such
capacity since 2018. Since July 2025, he has served as Chief Medical Director of T45 Labs, a Bay Area medical device incubator,
and since July 2018, he has served as Medical Director of the Atherosclerosis Imaging Core Laboratory. He has held the
post of Adjunct Professor at Swinburne University of Technology since 2024. Dr. Puri was Associate Professor (adjunct) at the Institute
for Intelligent Systems Research and Innovation at Deakin University from 2017 through April 2025.

He has published
over 450 original manuscripts in high-impact journals across a broad topic base including transcatheter structural heart
interventions for valvular heart disease and heart failure, atherosclerosis progression-regression and plaque imaging, and coronary
physiology/pharmacology. He is actively involved in developing novel device-based technologies in coronary, structural heart
disease, and interventional heart failure, and has co-founded and advises a range of medical start-up companies and larger
strategics.

Dr. Puri currently
serves as global co-principal investigator (“PI”) for the TRICAV-1 and TRICAV-2 FDA pivotal trials, a position
he has held since April 2022, and the ADVANCE-DCB first-in-man trial, which he has served as since September 2022. Since early 2025,
Dr. Puri has been national principal investigator for the ALLAY-HFrEF trial. He also serves on the global steering committees of
multiple other pivotal trials in the aortic, mitral and tricuspid valve therapy space.

Dr. Puri completed his
medical degree (MBBS) and a Ph.D. in medicine/cardiology at the University of Adelaide in 2001 and 2014, respectively, during
which time he also held an internship, residency, and a fellowship in internal medicine and cardiology at the Royal Adelaide Hospital.Dr.
Puri then completed subspecialty training in interventional and structural heart disease at the Québec Heart and Lung Institute
in Quebec City from 2014 to 2017, at the Rennes University Hospital during 2017, and was appointed visiting Senior Staff Cardiologist
at Royal Adelaide Hospital in 2017 and 2018, and at the Universitätsspital Zürich in 2018.He received his FRACP degree
from the Royal Australasian College of Physicians in 2008.

William T. Abraham,
M.D., FACP, FACC, FAHA, FESC, FRCPE has served as a director since July 2025.

Dr. Abraham, age 66, has
served as a member of our board of directors since August 2025. He has also served as a member of the board of directors of scPharmaceuticals
Inc. (Nasdaq: SCPH) since February 2021.

Dr. Abraham joined Cardiac
Dimensions as Chief Medical Officer in September 2025 having served as Chief Medical Officer of V-Wave Ltd. (now a subsidiary of Johnson
& Johnson) since March 2019. Over his career, he has participated as a site principal investigator, national or international principal
investigator, and/or on the executive or steering committees in numerous multicenter clinical drug and device trials. He was the lead
author of the MIRACLE cardiac resynchronization therapy trial (2002), a principal investigator of the CHAMPION implantable hemodynamic
monitoring trial (2011), and a co-principal investigator of the COAPT percutaneous mitral valve repair trial (2018).

Dr. Abraham has authored
or co-authored more than 1,000 manuscripts, book chapters, and scientific papers published in peer-reviewed journals,
including The New England Journal of Medicine, The Lancet, and The Journal of the American Medical Association. His research
interests include the role of the kidney in heart failure, neurohormonal mechanisms in heart failure, sleep-disordered breathing, and
clinical drug and device trials in heart failure and cardiac transplantation.

Dr. Abraham received his
B.A. in Honors Philosophy from the University of Pittsburgh in 1982 and his M.D. from Harvard Medical School in 1986. He completed his
internal medicine residency (1986–1990) at the University of Colorado Health Sciences Center where he also completed fellowships
in cardiovascular disease and advanced heart failure/cardiac transplantation (1990–1993) and served on the faculty (1993-1997).
He then joined the faculty at the University of Cincinnati as Associate Professor of Medicine and Director, Section of Heart Failure
and Cardiac Transplantation from 1997–2000 and subsequently the University of Kentucky faculty as Chief of Cardiovascular Medicine
from 2000 to 2002. Dr. Abraham is Professor of Medicine, Physiology and Cell Biology at The Ohio State University Wexner Medical Center
having served as the Chief of Cardiovascular Medicine at The Ohio State University from 2002 to 2019. He is board-certified in internal
medicine and advanced heart failure and transplant cardiology. We believe that Dr. Abraham’s clinical-trial leadership, academic
expertise, regulatory experience, and board service at other life sciences companies qualify him to serve as a member of our board of
directors.

Family
Relationships

There
are no family relationships between or among any of the current directors, executive officers or persons nominated or charged to become
directors or executive officers.

Number
and Terms of Office of Officers and Directors

Our
business and affairs are organized under the direction of our board of directors. Upon the consummation of this offering, our board of
directors will consist of five directors, including two executive directors and three independent directors.

Our
Amended and Restated Bylaws provide that the number of directors will be fixed by the board of directors within a range of between 1
and 9 directors. The directors need not be stockholders unless so required by our certificate of incorporation. The minimum or maximum
number may be increased or decreased from time to time only by an amendment to the bylaws, which power belongs exclusively to our board
of directors.

Our
officers are appointed by the board of directors and shall hold office at the discretion of the board of directors until their successors
are duly elected and qualified, unless sooner removed. Our board of directors is authorized to appoint officers to the offices set forth
in our bylaws.